| 0 (0%) | 04-16 18:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.2  |
1-year : | 2.4 |
| Resists | First : | 1.88 |
Second : | 2.05 |
| Pivot price | 1.79 |
|||
| Supports | First : | 1.6 |
Second : | 1.33 |
| MAs | MA(5) : | 1.69 |
MA(20) : | 1.79 |
| MA(100) : | 1.75  |
MA(250) : | 2.29 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 2.4 |
D(3) : | 7.8 |
| RSI | RSI(14): 36.1 |
|||
| 52-week | High : | 4.59 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GLT ] has closed above bottom band by 0.3%. Bollinger Bands are 34.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.66 - 1.68 | 1.68 - 1.68 |
| Low: | 1.57 - 1.59 | 1.59 - 1.6 |
| Close: | 1.58 - 1.6 | 1.6 - 1.62 |
Thu, 13 Apr 2023
UK County Court rules in favour of landlord imposing redevelopment break into renewal lease - Osborne Clarke
Wed, 19 Aug 2020
Onetai Station honey plus Taupō milk equals a new premium product - New Zealand Herald
Thu, 29 Nov 2018
Wayne-based Egalet has stopped manufacturing and promoting Arymo ER pain medicine - Philadelphia - The Business Journals
Wed, 31 Oct 2018
Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products - PR Newswire
Tue, 18 Oct 2016
Egalet Corporation (EGLT) in Focus: Stock Moves 9.5% Higher - Yahoo News
Tue, 09 Aug 2016
FDA panel recommends approval of Egalet's abuse-deterrent pain med - FiercePharma
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 45 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 81.2 (%) |
| Shares Short | 2,750 (K) |
| Shares Short P.Month | 3,000 (K) |
| EPS | -1.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.69 |
| Profit Margin | -5.8 % |
| Operating Margin | -1.8 % |
| Return on Assets (ttm) | 0.7 % |
| Return on Equity (ttm) | -27.2 % |
| Qtrly Rev. Growth | -14.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 30.71 |
| EBITDA (p.s.) | 1.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.93 |
| PEG Ratio | 0 |
| Price to Book value | 0.28 |
| Price to Sales | 0.05 |
| Price to Cash Flow | -2.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|